RxDoctor Payments Data

Leonard Sandler, MD

Cardiovascular Disease · Brick, NJNPI 1184603227

Payments from drug & device makers

$8,935in general payments, 2019–2025

Across 581 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$1K
  • Abbott$940
  • E.r. Squibb & Sons, L.L.C.$735
  • AstraZeneca$558
  • Johnson & Johnson$530
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,897100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,935 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,104,318
Medicare patients
2,306
Services billed
10,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban551$665,354
XareltoRivaroxaban243$295,589
EntrestoSacubitril/Valsartan118$132,464
BrilintaTicagrelor74$73,484
JardianceEmpagliflozin55$64,919
MultaqDronedarone Hcl64$59,746
FarxigaDapagliflozin Propanediol46$53,088
Repatha SureclickEvolocumab41$42,745
Repatha SyringeEvolocumab16$19,330
Icosapent Ethyl49$18,536
Metoprolol Succinate996$17,480
Praluent PenAlirocumab14$15,630
Dabigatran EtexilateDabigatran Etexilate Mesylate28$10,667
PradaxaDabigatran Etexilate Mesylate21$8,177
Valsartan220$6,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,039$665,354551 claims
Johnson & JohnsonXarelto$530$295,589243 claims
NovartisEntresto$1,452$132,464118 claims
AstraZenecaBrilinta, Farxiga$558$126,572120 claims
Boehringer IngelheimJardiance, Pradaxa$528$73,09576 claims
Sanofi-aventis U.S. LLCMultaq$266$59,74664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →